08:00 , Dec 19, 2011 |  BC Week In Review  |  Company News

Afexa, Valeant Pharmaceuticals deal

Valeant completed its acquisition of Afexa for C$0.85 per share, or about C$87.7 million ($85.7 million) (see BioCentury, Nov. 7). Afexa Life Sciences Inc. , Edmonton, Alberta   Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX), Mississauga,...
08:00 , Nov 7, 2011 |  BC Week In Review  |  Company News

Afexa, Valeant Pharmaceuticals deal

Valeant completed its tender offer for Afexa, and now holds 89.5 million shares, or 81.6% of Afexa's outstanding shares. Valeant said it would acquire the remaining Afexa shares in a subsequent acquisition transaction. Last month,...
07:00 , Oct 24, 2011 |  BC Week In Review  |  Company News

Afexa management update

Afexa Life Sciences Inc. (TSX:FXA), Edmonton, Alberta   Business: Nutraceuticals   Hired: Thomas Schlader as president and CEO, while remaining president of Valeant Pharmaceuticals International Inc. 's Valeant Canada Ltd. subsidiary  ...
07:00 , Oct 24, 2011 |  BC Week In Review  |  Company News

Afexa, Valeant Pharmaceuticals deal

Valeant extended its tender offer to acquire Afexa for C$0.85 per share, or about C$87.7 million ($87.2 million), to Oct. 27. At Oct. 17, 80.9 million shares, or about 73.8% of outstanding shares, had been...
07:00 , Oct 24, 2011 |  BC Week In Review  |  Company News

Afexa board of directors update

Afexa Life Sciences Inc. (TSX:FXA), Edmonton, Alberta   Business: Nutraceuticals   Appointed: Robert Chai-Onn as chairman, while remaining EVP, general counsel and corporate secretary of Valeant Pharmaceuticals International Inc.  ...
07:00 , Oct 10, 2011 |  BC Week In Review  |  Company News

Afexa, Paladin, Valeant Pharmaceuticals deal

Paladin said last week that no Afexa shares would be taken up when its offer expired at 8 p.m. EDT on Oct. 7 because a basic condition of its unsolicited tender offer to acquire Afexa...
07:00 , Oct 3, 2011 |  BC Week In Review  |  Company News

Afexa, Paladin, Valeant Pharmaceuticals deal

Valeant increased its tender offer to acquire Afexa to C$0.85 per share in cash after Paladin increased its unsolicited tender offer to acquire Afexa to C$0.81 per share in cash earlier in the week. Valeant's...
07:00 , Sep 19, 2011 |  BC Week In Review  |  Company News

Afexa, Paladin, Valeant Pharmaceuticals deal

Valeant began its tender offer to acquire Afexa for C$0.71 per share in cash, or about C$76 million ($75.9 million). The offer expires at 5 p.m. MST on Oct. 17. Separately last week, Paladin extended...
07:00 , Sep 5, 2011 |  BC Week In Review  |  Company News

Afexa, Valeant Pharmaceuticals deal

Valeant will acquire Afexa for C$0.71 per share in cash, or about C$76 million ($77.6 million). The price is a 20% premium to Afexa's close of C$0.59 on Aug. 29, before the deal was announced,...
07:00 , Aug 29, 2011 |  BC Week In Review  |  Company News

Afexa nutraceuticals news

The Toronto Stock Exchange said it will automatically defer acceptance of Afexa's new shareholder rights plan until Sept. 9. The exchange automatically defers acceptance of new plans until it is satisfied that the plan does...